



**TABLE OF CONTENTS**

I. Introduction.....1

II. Teva’s Patents Fail To Adequately Describe the Claimed Genus of Humanized Anti-CGRP Antagonist Antibodies Under *Ariad* and *AbbVie* .....1

    A. Teva’s Patents Disclose No Common Structure Correlated to Function.....1

    B. Teva’s Patents Fail To Disclose Representative Species.....2

III. There Was No Other Legally Sufficient Evidentiary Basis for a Reasonable Jury To Find for Teva .....5

    A. The Claimed Genus of Humanized Antibodies Was *Not* Well-Known .....5

    B. Whether a POSA “Could” Make More Humanized Anti-CGRP Antagonist Antibodies Is Not the Standard for Written Description .....6

    C. Unclaimed Rodent Antibodies Are Not Representative Species .....8

    D. Teva’s Claims Are “Extremely Broad” .....8

    E. Teva Fails To Distinguish *Halliburton* .....9

    F. Teva’s Tangential and Immaterial Credibility Challenges Cannot Avoid JMOL .....10

IV. Teva Lacks Written Description Under *Nuvo*.....11

V. Teva Provides No Legally Sufficient Basis To Sustain the Verdict on Enablement.....12

VI. In the Alternative, the Court Should Grant Lilly’s Request for a New Trial.....13

VII. Teva’s Wholly Speculative Trial Presentation Negates Its Future Lost Profits Award as a Matter of Law .....13

VIII. Conclusion .....15

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>Cases</b>	
<i>Abbott GmbH &amp; Co. v. Centocor Ortho Biotech Inc.</i> , 971 F. Supp. 2d 171 (D. Mass. 2013).....	4, 6
<i>AbbVie Deutschland GmbH &amp; Co. v. Janssen Biotech, Inc.</i> , 759 F.3d 1285 (Fed. Cir. 2014).....	<i>passim</i>
<i>Amgen Inc. v. Sanofi</i> , 872 F.3d 1367 (Fed. Cir. 2017).....	<i>passim</i>
<i>Ariad Pharms., Inc. v. Eli Lilly &amp; Co.</i> , 598 F.3d 1336 (Fed. Cir. 2010) (en banc).....	<i>passim</i>
<i>Baxalta Inc. v. Genentech, Inc.</i> , C.A. No. 17-509-TBD, 2018 WL 3742610 (D. Del. Aug. 7, 2018).....	3
<i>Bos. Sci. Corp. v. Johnson &amp; Johnson Inc.</i> , 679 F. Supp. 2d 539 (D. Del. 2010), <i>aff'd</i> , 647 F.3d 1353 (Fed. Cir. 2011) .....	7
<i>Brooktree Corp. v. Advanced Micro Devices, Inc.</i> , 977 F.2d 1555 (Fed. Cir. 1992).....	14, 15
<i>Eli Lilly &amp; Co v. Teva Pharms. Int'l GmbH</i> , 8 F.4th 1331 (Fed. Cir. 2021) .....	11
<i>Fail-Safe, L.L.C. v A.O. Smith Corp.</i> , 744 F. Supp. 2d 870 (E.D. Wis. 2010).....	15
<i>Guilloty Perez v. Pierluisi</i> , 339 F.3d 43 (1st Cir. 2003).....	10
<i>Halliburton Oil Well Cementing Co. v. Walker</i> , 329 U.S. 1 (1946).....	9
<i>Holland Furniture Co. v. Perkins Glue Co.</i> , 277 U.S. 245 (1928).....	9
<i>In re Hyatt</i> , 708 F.2d 712 (Fed. Cir. 1983).....	10
<i>Idenix Pharms. LLC v. Gilead Scis. Inc.</i> , 941 F.3d 1149 (Fed. Cir. 2019).....	13

*Juno Therapeutics, Inc. v. Kite Pharma, Inc.*,  
10 F.4th 1330 (Fed. Cir. 2021) .....5, 9

*Lam, Inc. v. Johns-Manville Corp.*,  
718 F.2d 1056 (Fed. Cir. 1983).....15

*MorphoSys AG v. Janssen Biotech, Inc.*,  
358 F. Supp. 3d 354 (D. Del. 2019).....13

*Nuvo Pharm. (Ir.) Designated Activity Co. v. Dr. Reddy’s Lab’ys Inc.*,  
923 F.3d 1368 (Fed. Cir. 2019).....12

*O’Reilly v. Morse*,  
56 U.S. 62 (1853).....9, 10

*Oiness v. Walgreen Co.*,  
88 F.3d 1025 (Fed. Cir. 1996).....14, 15

*Power Integrations, Inc. v. Fairchild Semiconductor Int’l, Inc.*,  
843 F.3d 1315 (Fed. Cir. 2016).....5

*Reeves v. Sanderson Plumbing Prods., Inc.*,  
530 U.S. 133 (2000).....11

*Regents of the Univ. of Minn. v. Gilead Scis. Inc.*,  
No. 21-2168, 2023 WL 2358853 (Fed. Cir. Mar. 6, 2023).....4

*In re Ruschig*,  
379 F.2d 990 (C.C.P.A. 1967) .....6

*Standard Oil Co. v. Am. Cyanamid Co.*,  
774 F.2d 448 (Fed. Cir. 1985).....7

*Teva Pharms. Int’l GmbH v. Eli Lilly & Co.*,  
8 F.4th 1349 (Fed. Cir. 2021) .....9

*Wyeth & Cordis Corp. v. Abbott Lab’ys*,  
720 F.3d 1380 (Fed. Cir. 2013).....12

**Federal Statutes**

35 U.S.C. § 112, ¶ 1 .....7

35 U.S.C. § 112, ¶ 6.....10

## TABLE OF ABBREVIATIONS

Abbreviation	Description
'045 patent	U.S. Patent No. 8,586,045
'907 patent	U.S. Patent No. 9,884,907
'908 patent	U.S. Patent No. 9,884,908
<b><i>Bold and italicized</i></b>	Emphasis added unless indicated otherwise
BBB	Blood-brain barrier
Br.	Eli Lilly and Company's Memorandum in Support of Its Motion for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(B) and/or a New Trial Under Fed. R. Civ. P. 59
CGRP	Calcitonin gene-related peptide
CCW	Closed cranial window
Ex. ____	Refers to Exhibits to the accompanying Declaration of Emily R. Gabranski in Support of Lilly's Motion for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(b) and/or a New Trial Under Fed. R. Civ. P. 59, unless otherwise noted
IPR	<i>Inter partes</i> review
JMOL	Judgment as a matter of law
Lilly	Eli Lilly and Company
Opp.	Plaintiffs' Opposition to Eli Lilly and Company's Motion for Judgment as a Matter of Law Under Fed. R. Civ. P. 50(B) and/or a New Trial Under Fed. R. Civ. P. 59
POSA	Person of ordinary skill in the art
PTAB	Patent Trial and Appeal Board
PTX-____ or TX____	Refers to exhibits admitted during trial
Teva	Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.
Teva's patents	U.S. Patent Nos. 8,586,045; 9,884,907; and 9,884,908

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.